Monograph

B01AX05 - Fondaparinux

Propably not porphyrinogenic

Rationale

Synthetic substance. The dose is in larger parts not metabolised. No clinically significant CYP-interactions observed.

Chemical description

Synthetic and selective inhibitor of activated factor X. Administered subcutaneously, 2.5 mg/d, for prevention agaist thromoembolic episodes in patients undergoing orthopedic surgery. Excreted in unchanged form to 64-77%. Has been shown not to inhibit the metabolism of CYP metabolized drugs.

Similar drugs

Explore alternative drugs in similar therapeutic classes B01A / B01AX or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames

Arixtra

Arixtra · Fondaparinux

Arixtra

Acute Porphyria Drug Database

Monograph